Intracranial efficacy and safety of furmonertinib 160mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and are correlated with poor outcomes.